We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Beam Therapeutics Stock Soars 21% in Three Months: Here's Why
Read MoreHide Full Article
Key Takeaways
BEAM stock rose 21% over the past three months, driven by positive BEAM-302 phase I/II data in AATD.
BEAM plans an accelerated approval path for BEAM-302 and expects to initiate a global cohort in H2 2026.
BEAM ended Q1 2026 with about $1.2B in cash. Funding is expected to support operations into mid-2029.
Shares of Beam Therapeutics (BEAM - Free Report) have risen 21% over the past three months against the industry’s 4.5% decline, primarily driven by positive clinical developments. Investor sentiment has also been bolstered by rapid regulatory progress across the company’s pipeline, strengthening confidence in its base-editing platform and in its strong financial position.
Image Source: Zacks Investment Research
Strong Clinical Data From BEAM-302
An important catalyst behind the stock’s rally has been the encouraging early data announced in late March from an ongoing phase I/II dose-escalation study evaluating its pipeline candidate, BEAM-302, for the treatment of patients with alpha-1 antitrypsin deficiency (AATD), across multiple dose levels. BEAM-302 is a liver-targeting lipid-nanoparticle formulation of base editing reagents designed to correct the disease-causing PiZ mutation.
The study demonstrated that BEAM-302 produced durable increases in functional AAT levels, significant reductions in mutant Z-AAT and the generation of corrected M-AAT, with a favorable safety profile across single doses up to 75 mg.
BEAM plans to advance BEAM-302 via an accelerated approval pathway, based on a primary endpoint of AAT biomarkers evaluated for more than 12 months, with the 60 mg selected as the optimal biological dose for further development.
To support a future biologics license application (BLA), the company anticipates enrolling approximately 50 additional patients with AATD-related lung disease, with or without liver involvement, by expanding its ongoing open-label phase I/II study. BEAM expects to initiate the global cohort in the second half of 2026.
Beyond BEAM-302, investors have become increasingly optimistic about BEAM's broader pipeline. The company remains on track to submit a BLA for risto-cel, its investigational sickle cell disease therapy, by the end of 2026.
Beam Therapeutics is also expanding its genetic disease pipeline by developing BEAM-301 for the treatment of glycogen storage disease type 1a in a phase I/II dose-exploration study. Initial data from the study are expected in 2026.
The company expanded its liver-targeted genetic disease franchise with BEAM-304 for the treatment of phenylketonuria and plans to file an investigational new drug application with the FDA in 2026.
Dosing in the ongoing phase I healthy volunteer study, evaluating BEAM-103, an anti-CD117 monoclonal antibody for the treatment of SCD, is expected to be completed in 2026.
BEAM’s Strong Financial Position
Beam has historically maintained a large cash runway, which reassures investors that it can fund ongoing clinical development without near-term dilution concerns.
The company reported approximately $1.2 billion in cash, cash equivalents and marketable securities at the end of the first quarter of 2026. Management expects its cash position, including the initial $100 million received and an anticipated additional $100 million under its financing agreement with Sixth Street, to support operations into mid-2029.
BEAM’s Zacks Rank & Stocks to Consider
Beam Therapeutics currently carries a Zacks Rank #3 (Hold).
Over the past 30 days, earnings per share estimates for Indivior Pharmaceuticals remained unchanged at $4.05 for 2026 and $4.27 for 2027. INDV shares have risen 7% year to date.
Indivior Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 65.44%.
Over the past 30 days, estimates for Liquidia’s earnings per share remained unchanged at $2.97 for 2026 and $4.81 for 2027. LQDA shares have gained 108.3% year to date.
Liquidia’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 54.40%.
Over the past 30 days, earnings per share estimates for Immunocore’s 2026 were unchanged at 6 cents for 2026 and 87 cents for 2027. IMCR shares have lost 17.6% year to date.
Immunocore’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 46.66%.
View the Zacks #1 Rank List
Image: Bigstock
Beam Therapeutics Stock Soars 21% in Three Months: Here's Why
Key Takeaways
Shares of Beam Therapeutics (BEAM - Free Report) have risen 21% over the past three months against the industry’s 4.5% decline, primarily driven by positive clinical developments. Investor sentiment has also been bolstered by rapid regulatory progress across the company’s pipeline, strengthening confidence in its base-editing platform and in its strong financial position.
Image Source: Zacks Investment Research
Strong Clinical Data From BEAM-302
An important catalyst behind the stock’s rally has been the encouraging early data announced in late March from an ongoing phase I/II dose-escalation study evaluating its pipeline candidate, BEAM-302, for the treatment of patients with alpha-1 antitrypsin deficiency (AATD), across multiple dose levels. BEAM-302 is a liver-targeting lipid-nanoparticle formulation of base editing reagents designed to correct the disease-causing PiZ mutation.
The study demonstrated that BEAM-302 produced durable increases in functional AAT levels, significant reductions in mutant Z-AAT and the generation of corrected M-AAT, with a favorable safety profile across single doses up to 75 mg.
BEAM plans to advance BEAM-302 via an accelerated approval pathway, based on a primary endpoint of AAT biomarkers evaluated for more than 12 months, with the 60 mg selected as the optimal biological dose for further development.
To support a future biologics license application (BLA), the company anticipates enrolling approximately 50 additional patients with AATD-related lung disease, with or without liver involvement, by expanding its ongoing open-label phase I/II study. BEAM expects to initiate the global cohort in the second half of 2026.
Beam Therapeutics Inc. Price and Consensus
Beam Therapeutics Inc. price-consensus-chart | Beam Therapeutics Inc. Quote
Multiple Upcoming Pipeline Catalysts
Beyond BEAM-302, investors have become increasingly optimistic about BEAM's broader pipeline. The company remains on track to submit a BLA for risto-cel, its investigational sickle cell disease therapy, by the end of 2026.
Beam Therapeutics is also expanding its genetic disease pipeline by developing BEAM-301 for the treatment of glycogen storage disease type 1a in a phase I/II dose-exploration study. Initial data from the study are expected in 2026.
The company expanded its liver-targeted genetic disease franchise with BEAM-304 for the treatment of phenylketonuria and plans to file an investigational new drug application with the FDA in 2026.
Dosing in the ongoing phase I healthy volunteer study, evaluating BEAM-103, an anti-CD117 monoclonal antibody for the treatment of SCD, is expected to be completed in 2026.
BEAM’s Strong Financial Position
Beam has historically maintained a large cash runway, which reassures investors that it can fund ongoing clinical development without near-term dilution concerns.
The company reported approximately $1.2 billion in cash, cash equivalents and marketable securities at the end of the first quarter of 2026. Management expects its cash position, including the initial $100 million received and an anticipated additional $100 million under its financing agreement with Sixth Street, to support operations into mid-2029.
BEAM’s Zacks Rank & Stocks to Consider
Beam Therapeutics currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Indivior Pharmaceuticals (INDV - Free Report) , Liquidia Corporation (LQDA - Free Report) and Immunocore (IMCR - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 30 days, earnings per share estimates for Indivior Pharmaceuticals remained unchanged at $4.05 for 2026 and $4.27 for 2027. INDV shares have risen 7% year to date.
Indivior Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 65.44%.
Over the past 30 days, estimates for Liquidia’s earnings per share remained unchanged at $2.97 for 2026 and $4.81 for 2027. LQDA shares have gained 108.3% year to date.
Liquidia’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 54.40%.
Over the past 30 days, earnings per share estimates for Immunocore’s 2026 were unchanged at 6 cents for 2026 and 87 cents for 2027. IMCR shares have lost 17.6% year to date.
Immunocore’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 46.66%.